Cellectis’ Innovative Manufacturing Plant for Allogeneic Cellular Therapies (IMPACT) located in Raleigh, North Carolina, US, was developed to improve the company’s production capabilities. It is used for clinical and commercial-scale production of the company’s allogeneic chimeric antigen receptor (CAR) T-cell products, known as Universal Chimeric Antigen Receptor T-cells (UCART). Announced in March 2019, the plant was developed with an investment of $68.
6m. The facility became operational in October 2021 and generated approximately 200 new jobs. Location Cellectis’ cellular therapies manufacturing facility is located in Sumner Business Park at 2500 Sumner Boulevard in Wake County, North Raleigh.
The company had leased the property through its subsidiary, Cellectis Biologics. Spread across 83.5 acres (33.
8 hectares), the business park is located on Old Wake Forest Road between US Route 1 and the Interstate 540 Interchange Outer Loop. It has parking areas and buildings with brick and glass fronts. Raleigh was selected due to strong support from the local government and its positive attitude towards innovative companies.
Details of Cellectis’ IMPACT facility Cellectis’ IMPACT facility is an 82,000ft (7,618m state-of-the-art, good manufacturing practices (GMP) compliant manufacturing facility dedicated to the development of UCART products. The company previously manufactured UCART for clinical trials, as well as starting materials through contract manufacturing organ.
